Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Palo Alto Networks Inc (PANW) vs Pfizer Inc (PFE) Price & Performance

Palo Alto Networks IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Palo Alto Networks Inc vs Pfizer Inc — how do they compare? Palo Alto Networks Inc trades at $336.21 (market cap $274.64B), while Pfizer Inc trades at $27.9 (market cap $158.39B). The key difference: Palo Alto Networks Inc is the larger of the two by market cap, and Pfizer Inc pays a 6.19% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals.

PANWPFE
Market Cap
$274.64B$158.39B
Sector
TechnologyHealth
52-Week High
$396.00$29.02
52-Week Low
$141.67$23.60
Enterprise Value
$273.60B$209.89B
Volume
29,869,932
Dividend Yield
6.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Palo Alto Networks Inc

Palo Alto Networks (PANW) trades at $336.98, up 1.12% today, with a bearish technical signal despite recent earnings beats. Revenue grew to $9.22B in FY2025, with strong gross margins of 71.94%, but valuation ratios are elevated (P/E 293.03, P/S 23.39). The company is set to join the S&P 500, reflecting its leadership in AI cybersecurity, though rising costs and premium pricing pose challenges.

Outlook remains positive due to AI-driven security demand and platformization strategy, but high valuation and competitive pressures warrant caution. Analyst consensus is bullish with a $410.48 price target, yet near-term volatility may persist as the stock digests recent gains and faces execution risks in a dynamic cybersecurity landscape.

Pfizer Inc

Pfizer (PFE) trades at $27.78, down 2.36% today, with a consensus price target of $28.33 suggesting modest upside. The stock shows mixed technical signals with bullish moving averages but neutral oscillators. Recent earnings have consistently beaten expectations, though revenue declined from pandemic peaks. The company maintains strong cash flow generation and a solid dividend yield of approximately 3.1%.

Pfizer presents a value opportunity with reasonable valuation metrics and dividend stability, but faces headwinds from post-COVID revenue normalization and patent expirations. The company's pipeline progress in obesity and oncology could drive future growth, though execution risks remain. Analyst sentiment leans cautious with 59% hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Palo Alto Networks Inc

Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.

Read more on PANW

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE